Oragenics Stock Forecast, Price & News

+0.02 (+2.57 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.42 million shs
Average Volume2.92 million shs
Market Capitalization$92.48 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive OGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter.

Oragenics logo

About Oragenics

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The company has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and production of lantibiotics, a peptide antibiotic that are naturally produced in gram-positive bacteria. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.65 out of 5 stars

Medical Sector

1370th out of 2,099 stocks

Pharmaceutical Preparations Industry

615th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Oragenics (NYSEAMERICAN:OGEN) Frequently Asked Questions

What stocks does MarketBeat like better than Oragenics?

Wall Street analysts have given Oragenics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Oragenics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Oragenics' next earnings date?

Oragenics is scheduled to release its next quarterly earnings announcement on Friday, June 18th 2021.
View our earnings forecast for Oragenics

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSEAMERICAN:OGEN) posted its earnings results on Sunday, May, 2nd. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.01.
View Oragenics' earnings history

How has Oragenics' stock price been impacted by COVID-19 (Coronavirus)?

Oragenics' stock was trading at $0.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OGEN stock has increased by 33.3% and is now trading at $0.7997.
View which stocks have been most impacted by COVID-19

When did Oragenics' stock split? How did Oragenics' stock split work?

Oragenics shares reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split.

Who are Oragenics' key executives?

Oragenics' management team includes the following people:
  • Dr. Frederick W. Telling, Exec. Chairman (Age 69, Pay $107.5k)
  • Mr. Michael O. Sullivan CPA, CFO, Sec., Treasurer & Interim Principal Exec. Officer (Age 65, Pay $297.21k)
  • Dr. Martin Handfield, Sr. VP of Discovery Research (Age 50, Pay $250.05k)
  • Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant

Who are some of Oragenics' key competitors?

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Celsion (CLSN), Jaguar Health (JAGX), Ampio Pharmaceuticals (AMPE), Biocept (BIOC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Amarin (AMRN), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA) and Achieve Life Sciences (ACHV).

What is Oragenics' stock symbol?

Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."

Who are Oragenics' major shareholders?

Oragenics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.37%), Geode Capital Management LLC (0.46%), Citadel Advisors LLC (0.32%), Northern Trust Corp (0.16%), Private Wealth Advisors (0.05%) and GSA Capital Partners LLP (0.04%). Company insiders that own Oragenics stock include Joseph Hernandez and Robert C Koski.
View institutional ownership trends for Oragenics

Which institutional investors are selling Oragenics stock?

OGEN stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP. Company insiders that have sold Oragenics company stock in the last year include Joseph Hernandez, and Robert C Koski.
View insider buying and selling activity for Oragenics
or view top insider-selling stocks.

Which institutional investors are buying Oragenics stock?

OGEN stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Citadel Advisors LLC, Northern Trust Corp, Private Wealth Advisors, and Jane Street Group LLC.
View insider buying and selling activity for Oragenics
or or view top insider-buying stocks.

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $0.80.

How much money does Oragenics make?

Oragenics has a market capitalization of $92.48 million. The biotechnology company earns $-26,430,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How many employees does Oragenics have?

Oragenics employs 7 workers across the globe.

What is Oragenics' official website?

The official website for Oragenics is www.oragenics.com.

Where are Oragenics' headquarters?

Oragenics is headquartered at 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States.

How can I contact Oragenics?

Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company can be reached via phone at 813 286 7900 or via email at [email protected]

This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.